Introduction
The implementation of clinical information systems across healthcare, and recent advances in technology have created unprecedented opportunities to study population health, basic science, and the effects of medical care at scale. Indeed, everyday healthcare comprises many natural experiments, through which we can explore the real-world evidence of clinical practice. In clinical settings, such information is captured within electronic health records (EHRs), which are recorded routinely as part of medical care and frequently form an essential part of care delivery.
The secondary use of EHRs for research purposes has proliferated in recent years. In the context of clinical cardiology, disease/procedurespecific national registries prospectively collect patient-level data, which is advantageous from both a clinical perspective (through audit and feedback of performance) and a research perspective (through understanding epidemiological results at scale). Equally, basic science research has benefitted from the large-scale data arising from advances in imaging technology, in silico and stem cell models, and genome-wide association studies. 1 However, the secondary use of large-scale data for research purposes is not without challenges. In this commentary article, we discuss some of the opportunities of using large-scale observational data for clinical cardiology, the importance of data quality in this context, and the implications data quality might have on downstream analyses and clinical applications.
Opportunities of using large-scale observational data in clinical cardiology
Randomized controlled trials (RCTs) are considered the gold standard for evidence evaluation. However, they are often limited to recruitment of patients without significant comorbidities who are often not reflective of routine clinical practice. In the context of clinical cardiology, this is particularly pertinent as it is often the elderly and comorbid patients that are those at highest risk of adverse complications from treatments/ interventions. To overcome this, there has been an expansion of using large-scale routinely collected data in clinical cardiology and basic science studies, which offers numerous opportunities.
For example, whilst RCTs are able to estimate the prognostic impact of an intervention, they are unable to quantify the clinical impact that an intervention has had nationally in terms of adverse clinical events, or from a health economic perspective. 2 Indeed, the use of national 'big data' can help to study heterogeneity in practice adoption and its clinical impact, 3 as well as the incidence, temporal trends, and clinical outcomes of potentially rare complications. 4 Moreover, to personalize treatments to individual patients, risk scores are frequently derived in clinical cardiology. Deriving risk scores using data from RCTs can result in limited predictive performance since the patient cohorts can include very different characteristics to those patients encountered in 'real world practice'. Routinely collected healthcare data can overcome many of these limitations, as the EHR collects important information around comorbidity or frailty, 5 and the risk score can be developed directly in the population in which the tool is to be used. For example, cardiovascular risk prediction tools widely used in primary care, such as QRISK, 6 are derived from relevant EHR systems.
Quality control in large-scale observational data and implications for clinical applications
Nevertheless, the aforementioned opportunities can only be realized if issues surrounding data quality of routinely collected health data are addressed. Traditional observational studies (e.g. prospective cohort studies) are subject to a study protocol, meaning such data follow predefined inclusion criteria and recording structures. This is not the case in EHRs and other routinely collected healthcare data, which has resulted in concerns surrounding data quality, storage and coding errors. 7 Data quality has been previously defined based on categories of: (i) completeness, (ii) correctness, (iii) concordance, (iv) plausibility, and (v) currency. 8 While, such categories of data quality are not necessarily confined to 'big data', EHRs do present at least two particular challenges that we focus on here. Firstly, as noted by Burnum, the introduction of computer systems and data recording has not improved data quality per se, but rather a greater quantity of bad data. 9 Namely, inaccuracies of coding in EHRs, registries or administrative databases are well documented, but improving such data quality issues requires data custodians and researchers to overcome complex barriers that are inherent in the generation and collection of EHR and administrative databases. 10, 11 Improving the documentation and guidelines for entering diagnostic codes could help improve this situation, but in the least, analyses should be based on stringent code-lists that are reported alongside any results/conclusions to aid reproducibility and interpretation. Involvement of patients in their own data collection and storage (e.g. through wearable technology or home monitoring systems) is another potential solution to minimize the implications that inaccurate coding might have on future analyses. 12, 13 Secondly, data completeness is particularly problematic in large-scale data. Routine collection of data often presents issues with missing values, which includes scenarios where: (i) clinical measurements should have been taken about a patient but are not recorded, (ii) patients are lost to follow-up, and (iii) missing information is reflective of decisions that have been made about the patient's care. This latter scenario, in particular, means that classic statistical frameworks/terminology of missing data, such as missing at random or missing not at random, are arguably of limited use to capture the complex observational processes within routinely collected healthcare data. Specifically, clinical decisions often drive the information that is recorded in a given EHR (e.g. some measurements will only be taken in certain situations). Similarly, the presence of an observation within an EHR is potentially informative of clinical outcomes.
14 For example, in primary care, the collection of patient data from general practitioner (GP) records is based on the attendance of a patient to their GP practice. Given that those with worse overall health status may visit their GP more regularly, the presence of a primary care observation can reveal something about a patient's underlying health. While so-called 'informative observation' cannot be solved with quality control as such, it does require an awareness within those using, analysing and interpreting large-scale EHR data. In all cases, without considerations of data completeness, downstream naive modelling will lead to biased results and potentially incorrect conclusions.
Ethics and consent processes of EHRs
In addition to quality control having implications for clinical cardiology from an analysis perspective, there are also considerations from an ethical and patient consent perspective. Many routinely collected datasets do not specifically consent patients for use of their data for research purposes, because such data are usually analysed anonymously and contain no patient identifiable information. This is particularly relevant when multiple datasets need to be linked for a certain study, and unique patient identifiers have to be used for such linkage processes (such as NHS number). For example, one might require linkage of electronic healthcare record data with hospital episode statistics (HES) and mortality data from the Office of National Statistics (ONS); pseudonymization is often used in such scenarios. Additionally, some electronic healthcare records have research governance in place that allows their use without patient consent. For example, in the UK, the National Institute for Cardiovascular Outcomes Research (NICOR), which holds several national cardiovascular registry databases, has support under the National Health Service to use patient information for medical research without informed consent. Nevertheless, accessing EHRs (and healthcare data in general) for research should be undertaken with data security and data protection as primary considerations; guidelines such as the General Data Protection Regulation (GDPR) will ideally help support this important aspect of quality control. In other words, maintaining our ability to access and use routinely collected healthcare data for research, requires a collective responsibility to ensure high-levels of quality control in terms of data collection, storage, protection and analysis.
Conclusion
In conclusion, quality control in large-scale data is paramount to ensure that the results and interpretations stemming from such data sources remain robust. Augmenting RCTs with large-scale observational data offers numerous opportunities, but this can only be achieved effectively if efforts are made to improve data quality. Issues such as informative observation and other biases inherent in EHRs should be acknowledged and accounted for in analyses to ensure that conclusions remain robust.
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